Evidence map›Paper›PMID 33691613›Full record

ArticleMolecular medicine (Cambridge, Mass.)2021

E2F1 copy number variations in germline and breast cancer: a retrospective study of 222 Italian women.

Maria Santa Rocca, Clara Benna, Elena Goldin, Andrea Di Nisio, Luca De Toni, Ilaria Cosci, Alberto Marchet, Donato Nitti, Carlo Foresta

Open access · goldAbstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Maria Santa RoccaDepartment of Medicine, Unit of Andrology and Reproductive Medicine, University Hospital Padua, Via N. Giustiniani 2, 35128, Padua, Italy.
Clara BennaDepartment of Surgery Oncology and Gastroenterology, University of Padua, Padua, Italy.
Elena GoldinBreast Unit, Azienda ULSS n.8 Berica, Vicenza, Italy.
Andrea Di NisioDepartment of Medicine, Unit of Andrology and Reproductive Medicine, University Hospital Padua, Via N. Giustiniani 2, 35128, Padua, Italy.
Luca De ToniDepartment of Medicine, Unit of Andrology and Reproductive Medicine, University Hospital Padua, Via N. Giustiniani 2, 35128, Padua, Italy.
Ilaria CosciVeneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Alberto MarchetMultidisciplinary Day-Surgery Unit, University Hospital Padua, Padua, Italy.
Donato NittiDepartment of Surgery Oncology and Gastroenterology, University of Padua, Padua, Italy.
Carlo ForestaDepartment of Medicine, Unit of Andrology and Reproductive Medicine, University Hospital Padua, Via N. Giustiniani 2, 35128, Padua, Italy. carlo.foresta@unipd.it.ORCID 0000-0002-6576-2183
University of Padua · ITIstituto Oncologico Veneto · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer is the most common neoplasia among women in developed countries. The risk factors of breast cancer can be distinguished in modifiable and unmodifiable factors and, among the latter, genetic factors play a key role. Copy number variations (CNVs) are genetic variants that are classified as rare when present in less than 1% of the healthy population. Since rare CNVs are often cause of diseases, over the last years, their contribution in carcinogenesis has become a relevant matter of study. E2F1 is a transcriptional factor that plays an important role in regulating cell cycle and apoptosis. Its double and conflicting role is the reason why it acts both as oncogene and as tumour suppressor, depending on cell context. Since anomalies in expression or in number of copies of E2F1 have been related to several cancers, we aimed to study number of germline copies of E2F1 in women with breast cancer in order to better elucidate their contribution as predisposing factor to this tumour.

methodsWe performed, hence, a retrospective study on 222 Italian women with breast cancer recruited from October 2002 to December 2007. TaqMan CNV assay and Real-Time PCR were carried out to analyse, respectively, E2F1 CNV and E2F1 expression in the subjects of the study. Chi square test or Fisher's exact test and Student's t-test were used to calculate the frequency of CNVs and differences in continuous variables between groups, respectively.

resultsIntriguingly, we found that 10/222 (4.5%) women with breast cancer had more copies than controls (0/200, 0%), furthermore, the number of copies positively correlated with E2F1 gene expression in breast cancer tissue, suggesting that the constitutive gain of the gene could translate into an increased risk of genomic instability. Additionally, we found that altered E2F1 copies were present prevalently in the patients with contralateral breast cancer (20%) and all of them had a positive family history, both typically associated with hereditary cancer.

conclusionsOur findings suggest that copy number variations of E2F1 might be a susceptibility factor for breast cancer, however, further studies on large cohorts are to be performed in order to better delineate the phenotype linked to the gain of E2F1 copies.

Indexed as

AgedBreast NeoplasmsDNA Copy Number VariationsE2F1 Transcription FactorFemaleGenetic Predisposition to DiseaseGerm CellsHumansItalyMiddle AgedRetrospective StudiesE2F1 protein, humanE2F1 Transcription FactorBiomarkerBreast cancerCNVCopy number variationsE2F1

Identifiers

PMID33691613
PMCPMC7948349
OpenAlexW3133868993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.